我们对《关于南昌苏吴健康产业管理中心(有限合伙)拟清算退出的议案》 进行了认真审阅,一致认为:基于南昌苏吴健康产业管理中心(有限合伙)运行 的实际情况,现投资期届满,经全体合伙人协商一致决定启动相关清算工作。不 会对公司的日常经营活动产生实质性影响,也不存在损害公司和全体股东尤其是 中小股东利益的情形,全体独立董事一致同意公司清算并退出产业基金的事项。 江苏吴中医药发展股份有限公司独立董事 关于第十届董事会第八次会议相关事项的独立意见 (2023) 第 04 号 作为江苏吴中医药发展股份有限公司(以下简称"公司")的独立董事,我 们依据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司独立董 事规则》《上海证券交易所股票上市规则》及《公司章程》,本着对公司及全体 股东负责的态度和独立、客观、公正的原则,基于独立判断的立场,就公司第十 届董事会第八次会议相关事项发表独立意见如下: 一、关于第一期员工持股计划预留份额分配的事项 1、公司第一期员工持股计划预留份额的分配事项根据此前公司披露并实施 的《公司第一期员工持股计划》相关规定进行,决策程序合法、有效,本次预留 份额分配事项不存在损害公司及全体股东利益 ...

证券代码：600200 证券简称：江苏吴中 公告编号：临2023-056 江苏吴中医药发展股份有限公司（以下简称"公司"）第十届监事会第八次 会议通知于 2023 年 8 月 18 日以书面或电子邮件等形式发出，会议于 2023 年 8 月 28 日在公司会议室举行。会议应到监事 3 人，实到监事 3 人。会议的召开符 合《公司法》和相关法律法规以及《公司章程》《监事会议事规则》的有关规定。 会议由监事会主席吴振邦先生主持，会议经过审议，以书面投票表决方式通过了 如下决议： 一、审议通过了江苏吴中医药发展股份有限公司 2023 年半年度报告与报告 摘要 监事会经审核后认为：公司 2023 年半年报的编制和审议程序符合《公司法》 《上海证券交易所股票上市规则》等法律法规、《公司章程》等规章制度的要求； 半年报全文及正文的内容和格式符合：《公开发行证券的公司信息披露内容与格 式准则第 3 号——半年度报告的内容与格式（2021 年修订）》的特别规定,以及 上海证券交易所《关于做好主板上市公司 2023 年半年度报告披露工作的重要提 醒》的要求,半年报真实地反映了公司 2023 年上半年度的经营管理和财务状况等 事 ...

证券代码：600200 证券简称：江苏吴中 公告编号：临 2023-059 江苏吴中医药发展股份有限公司 关于第一期员工持股计划预留份额分配的公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 江苏吴中医药发展股份有限公司（以下简称"公司"）于 2023 年 8 月 28 日分别召开了第十届董事会第八次会议和第十届监事会第八次会议，审议通过了 《关于第一期员工持股计划预留份额分配的议案》。同意第一期员工持股计划预 留份额 155.2960 万份由符合条件的不超过 10 名认购对象认购，对应公司股份 42.20 万股，根据《公司第一期员工持股计划》和 2022 年第一次临时股东大会 的相关授权，本次预留份额的分配事项在董事会审批权限范围内，无需提交公司 股东大会审议。现将具体情况公告如下： 一、员工持股计划的实施进展 1、2021 年 12 月 16 日，公司召开了第十届董事会 2021 年第四次临时会议 （通讯表决），审议通过了《关于<江苏吴中医药发展股份有限公司第一期员工 持股计划（草案）>及其摘要的议案》《关于<江苏吴中医药发 ...

证券代码：600200 证券简称：江苏吴中 公告编号：临 2023-057 江苏吴中医药发展股份有限公司关于非公开发行 募集资金 2023 年上半年存放与实际使用情况的专项报告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求（2022 年修订）》和《上海证券交易所上市公司自律监管指引第 1 号——规范 运作（2022 年）》有关规定，现将本公司 2023 年上半年募集资金存放与使用情 况说明如下： 一、募集资金基本情况 (一) 实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于核准江苏吴中实业股份有限公司非公开发 行股票的批复》(证监许可[2015]2084号)核准，本公司获准非公开发行不超过 4,538万股新股(以下简称"本次发行")。本次发行实际发行数量为41,046,070 股，发行对象为6名，发行价格为12.52元/股，募集资金总额513,896,796.40元 (含发行费用)。扣除发行费用合计人民币11,519,544.24元后，本次募 ...

证券代码：600200 证券简称：江苏吴中 公告编号：临 2023-054 江苏吴中医药发展股份有限公司 关于向特定对象发行股票申请 公司与相关中介机构将按照上述《问询函》的要求，对《问询函》中的相关 问题进行逐项落实，并及时提交对《问询函》的回复，回复内容将通过临时公告 方式及时披露，并通过上交所发行上市审核业务系统报送相关文件。 公司本次向特定对象发行股票事项尚需通过上交所审核，并获得中国证券监 督管理委员会（以下简称"中国证监会"）作出同意注册的决定后方可实施，最 终能否通过上交所审核，并获得中国证监会同意注册的决定及其时间尚存在不确 定性。公司将根据该事项的进展情况及时履行信息披露义务，敬请广大投资者注 意投资风险 特此公告。 江苏吴中医药发展股份有限公司 董事会 2023 年 8 月 23 日 收到上海证券交易所审核问询函的公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 江苏吴中医药发展股份有限公司（以下简称"公司"）于 2023 年 8 月 21 日收到上海证券交易所（以下简称"上交所"）出具的《关于江苏吴中医药发 ...

上海证券交易所文件 ─────────────── 上证上审（再融资）〔2023〕601 号 关于江苏吴中医药发展股份有限公司向特定 对象发行股票申请文件的审核问询函 江苏吴中医药发展股份有限公司、中山证券有限责任公司： 根据《证券法》《上市公司证券发行注册管理办法》《上海 证券交易所上市公司证券发行上市审核规则》等有关法律、法规 及本所有关规定等，本所审核机构对江苏吴中医药发展股份有限 公司（以下简称发行人或公司）向特定对象发行股票申请文件进 行了审核，并形成了首轮问询问题。 1.关于本次募投项目必要性 根据申报材料，1）江苏吴中医药集团研发及产业化基地一 期项目将进一步扩大现有产品的生产规模并增加其他产品的生 1 产线，为公司现有在研产品与未来新药研发提供研发与生产基地， 为制药公司和新药研发公司客户提供从临床前到商业化的研发 生产一体化服务，完善公司在 CDMO 业务的产业布局。2）报告 期内，公司主营业务以医药业务为主，贸易业务为辅，医药业务 可分为医药工业和医药商业，医药工业指发行人自营产品的生产 经营，医药商业指医药配送业务。3）本项目建成后，苏药厂将 停产，现有产品迁移至本项目生产。 请发行人说 ...

证券代码：600200 证券简称：江苏吴中 公告编号：临 2023-039 江苏吴中医药发展股份有限公司 关于参加沪市主板生物医药行业上市公司2022年年报集体 业绩说明会暨2023年第一季度业绩说明会的公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 重要内容提示： 投资者可于 2023 年 05 月 05 日（星期五）至 05 月 11 日（星期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 lirui@600200.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 江苏吴中医药发展股份有限公司（以下简称"公司"）于 2023 年 4 月 27 日披露了公司 2022 年度报告及 2023 年第一季度报告，为便于广大投资者更全面 深入地了解公司 2022 年度及 2023 年一季度经营成果、财务状况，同时更加充分 地向投资者展示生物医药行业发展情况，公司计划于 2023 年 5 月 12 日下午 15:00-16:00 参加沪市主板生物医药行业上市公司 2022 年年报集体 ...

Financial Performance - In 2022, the company achieved a consolidated net profit attributable to shareholders of -76,197,270.30 CNY, a decrease of 435.43% compared to the previous year's profit of 22,716,282.29 CNY[5]. - The company's operating income for 2022 was 2,026,232,836.21 CNY, representing a year-on-year increase of 14.12% from 1,775,450,710.11 CNY in 2021[21]. - The net cash flow from operating activities was 56,273,913.03 CNY, a significant decrease of 87.43% compared to 447,643,667.01 CNY in the previous year[21]. - The company's net assets attributable to shareholders decreased by 2.77% to 1,803,693,253.17 CNY at the end of 2022, down from 1,855,013,445.80 CNY in 2021[21]. - The company reported a net profit attributable to shareholders after deducting non-recurring gains and losses of -96,516,313.05 CNY in 2022, compared to -87,969,266.96 CNY in 2021[21]. - The company reported a net profit attributable to the parent company of CNY -76,197,300.00, indicating a loss[75]. - The gross profit reached CNY 579,661,500.00, reflecting a 13.23% increase year-over-year[75]. - The total revenue for the company was CNY 67,219.24 million, reflecting a year-on-year increase of 9.73%[113]. Strategic Developments - The company does not plan to distribute profits or increase capital reserves for the fiscal year 2022 due to the negative net profit[5]. - The company has acknowledged the presence of industry risks that may impact future development, as detailed in the management discussion section[8]. - The company’s future plans and strategic developments are subject to investment risks, and no substantial commitments have been made to investors[6]. - The company is actively exploring equity cooperation models and expanding its CDMO business in small molecule and biologics sectors[34]. - The company is committed to enhancing its internal controls and exploring innovative sales models to adapt to new industry policies and market dynamics[104]. - The company is focusing on high-end generic drugs and the consistency evaluation of existing products in its R&D strategy[116]. - The company is committed to enhancing its research and development capabilities to drive innovation in the pharmaceutical sector[109]. Research and Development - The company optimized its R&D management structure, establishing a comprehensive management system for pharmaceutical R&D with dedicated research institutes for innovative drugs and generics[33]. - The company has established a comprehensive product layout in key therapeutic areas, including antiviral, anti-tumor, and immunomodulatory drugs, enhancing its competitive edge[103]. - The company is focusing on the development of new drugs for gastrointestinal and respiratory diseases, with multiple patents filed in recent years[109]. - The company has ongoing research and development projects, with a focus on new drug development and consistency evaluation for existing products[123]. - The company’s R&D investment for the reporting period amounted to RMB 44,851.60 million, with a capitalization ratio of 39.80%[125]. - The major R&D projects included a respiratory system traditional Chinese medicine project with an investment of RMB 32.74 million and an anti-tumor project with RMB 370.87 million, where RMB 328.87 million was capitalized[126]. Market Trends and Industry Insights - The pharmaceutical manufacturing industry in China reported a cumulative revenue of CNY 2,911.14 billion in 2022, with a year-on-year growth rate of -1.60%[42]. - The chemical pharmaceutical industry remains a dominant segment in the Chinese market, driven by increasing healthcare demands and an aging population[45]. - The overall medical aesthetics market is experiencing a shift towards non-surgical treatments, which are preferred by consumers due to lower risks and shorter recovery times[46]. - The market size for hyaluronic acid-based dermal fillers in China was RMB 6.4 billion in 2021, with a CAGR of 19.7% from 2017 to 2021, and is projected to reach RMB 19.6 billion by 2026, reflecting a CAGR of 25.0% from 2021 to 2026[47]. - The market for recombinant collagen-based functional skincare products is forecasted to reach RMB 64.5 billion by 2027, with a CAGR of 55.0% from 2022 to 2027[52]. Regulatory Environment - In 2022, over 320 new policies related to the pharmaceutical industry were introduced, indicating a significant regulatory shift that may impact market dynamics[54]. - The Chinese government is focusing on enhancing the medical and pharmaceutical sectors through various strategic plans, emphasizing innovation and quality assurance[55]. - The National Medical Products Administration (NMPA) has initiated a public consultation on the draft regulations for the implementation of the Drug Administration Law, encouraging the development of drugs for rare diseases and children's medications[59]. - The NMPA's new regulations on drug registration aim to enhance the management of chemical raw materials and improve the drug approval process, reflecting the government's commitment to streamline regulations[60]. Corporate Governance and Management - The company has a well-defined corporate governance structure that complies with relevant laws and regulations, ensuring effective checks and balances[162]. - The company emphasizes investor relations management, providing multiple channels for communication with investors[164]. - The company has implemented a stock incentive plan and an employee stock ownership plan, which were approved in the shareholder meetings[166][167]. - The company held five board meetings in 2022, with two conducted in person and three via communication methods[185]. - The company has established a "Major Event Reporting System" to ensure timely reporting of significant events from subsidiaries to enhance decision-making efficiency and risk management[198]. Human Resources and Talent Development - The company has implemented a wide salary policy based on job responsibilities and performance, ensuring competitive compensation and benefits[193]. - The company emphasizes talent development through a three-tier training program, including new employee training and leadership development[194]. - The company’s executive compensation is directly linked to performance and responsibilities, enhancing the effectiveness of its incentive mechanisms[197]. - The employee composition includes 329 production personnel, 251 sales personnel, 176 technical personnel, 38 financial personnel, and 215 administrative personnel[192].

Financial Performance - The company's operating revenue for Q1 2023 was CNY 611,782,589.11, representing a year-on-year increase of 37.69%[5] - The net profit attributable to shareholders of the listed company reached CNY 28,152,696.06, a significant increase of 269.61% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 5,984,226.17, up by 67.86% year-on-year[5] - The company's basic earnings per share for Q1 2023 was CNY 0.040, an increase of 259.29% year-on-year[5] - Net profit for Q1 2023 was RMB 27,581,716.49, compared to RMB 7,016,937.24 in Q1 2022, reflecting a significant increase of approximately 292.5%[19] - The total comprehensive income for Q1 2023 was ¥27,357,334.45, up from ¥7,160,392.95 in Q1 2022[20] - Basic and diluted earnings per share for Q1 2023 were both ¥0.04, compared to ¥0.01 in Q1 2022, indicating improved profitability[20] Assets and Liabilities - The total assets at the end of Q1 2023 were CNY 4,014,492,239.99, reflecting a 2.68% increase from the end of the previous year[6] - The company's total assets as of March 31, 2023, amounted to RMB 4,014,492,239.99, compared to RMB 3,909,731,794.92 at the end of 2022, showing a growth of about 2.7%[16] - Current assets totaled RMB 2,833,932,137.70 as of March 31, 2023, an increase from RMB 2,729,547,553.76 at the end of 2022, representing a growth of approximately 3.8%[14] - Current liabilities increased to RMB 1,965,843,729.82 as of March 31, 2023, from RMB 1,855,556,809.51 at the end of 2022, indicating a rise of about 5.9%[16] - Long-term liabilities decreased to RMB 194,415,344.80 as of March 31, 2023, down from RMB 230,600,842.08 at the end of 2022, reflecting a decline of approximately 15.7%[16] - Total liabilities reached approximately $2.09 billion, with current liabilities at $1.86 billion and non-current liabilities at $230.6 million[27] - Shareholders' equity totaled approximately $1.82 billion, with a significant portion being capital reserves of $1.40 billion[28] Cash Flow - The net cash flow from operating activities was negative at CNY -80,312,170.27, a decline of 284.20% compared to the previous year[5][8] - Cash inflows from operating activities totaled ¥1,861,212,711.77 in Q1 2023, compared to ¥1,538,319,753.00 in Q1 2022, reflecting a growth of approximately 20.9%[22] - The net cash flow from operating activities was negative at -¥80,312,170.27 for Q1 2023, a decline from a positive ¥43,601,145.05 in Q1 2022[22] - Cash inflows from investment activities were ¥225,751,257.64 in Q1 2023, significantly higher than ¥86,880,669.00 in Q1 2022[23] - The net cash flow from financing activities for Q1 2023 was ¥148,902,129.12, compared to ¥123,207,093.37 in Q1 2022, showing an increase of approximately 20.9%[23] - The company reported a total cash inflow from financing activities of ¥696,259,829.84 in Q1 2023, compared to ¥572,340,828.62 in Q1 2022[23] Investment and Other Income - The company reported a significant increase in investment income of 708.20%, attributed to the transfer of equity in Changzheng Xinkai[7] - The company reported a significant increase in investment income, reaching RMB 23,655,227.13 in Q1 2023, compared to RMB 2,926,920.16 in Q1 2022, indicating a growth of approximately 707.5%[19] - The company has a long-term investment in equity amounting to approximately $426 million, showcasing its commitment to strategic investments[26] Other Financial Metrics - The weighted average return on equity increased by 1.14 percentage points to 1.55%[5] - The company experienced a 91.19% decrease in other current assets due to the redemption of financial products[7] - The construction of a new pharmaceutical base has led to a 71.35% increase in construction in progress[7] - The company experienced a decrease in other comprehensive income, with a net amount of -¥224,382.04 in Q1 2023, compared to ¥143,455.71 in Q1 2022[20] - The company reported a net loss of approximately $416.54 million, which is a slight improvement from the previous quarter[28] - The total amount of short-term borrowings was approximately $1.37 billion, indicating reliance on external financing[27] - The company has a deferred tax asset of approximately $2.75 million, which may provide future tax benefits[26]

Financial Performance - The company's operating revenue for Q3 2022 was ¥594,281,822.27, representing a year-on-year increase of 37.19%[7] - The net profit attributable to shareholders was -¥27,415,072.91, with a year-to-date net profit of -¥46,827,361.12, reflecting a decrease of 194.81% compared to the same period last year[7] - The basic earnings per share for the quarter was -¥0.039, a decrease of 195.27% year-on-year[9] - Total revenue for the first three quarters of 2022 was CNY 1,380,375,163.96, a decrease of 5.93% compared to CNY 1,467,782,116.49 in the same period of 2021[30] - Net profit for Q3 2022 was a loss of CNY 48,381,746.93, compared to a profit of CNY 47,910,931.43 in Q3 2021, indicating a significant decline[33] - The net profit attributable to the parent company was -$46.83 million, compared to a profit of $49.39 million in the same period last year, indicating a significant decline[37] - The total comprehensive income amounted to -$49.08 million, down from $32.77 million year-over-year[37] - The basic and diluted earnings per share were both -$0.066, compared to $0.069 in the previous year[39] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,823,823,724.11, an increase of 1.74% from the end of the previous year[9] - Total current assets as of September 30, 2022, amounted to RMB 2,739,426,823.28, an increase from RMB 2,684,319,610.62 as of December 31, 2021, reflecting a growth of approximately 2.05%[25] - Total liabilities reached CNY 1,975,015,526.92 in Q3 2022, up from CNY 1,881,410,098.21, reflecting an increase of 4.99%[30] - Non-current assets totaled CNY 1,084,396,900.83, slightly up from CNY 1,074,018,034.94, indicating a growth of 0.30%[30] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥161,602,511.28, indicating a significant decline in cash inflow[9] - Cash flow from operating activities generated a net outflow of -$161.60 million, a decrease from a net inflow of $291.74 million in the same period last year[39] - Cash inflow from investment activities was $272.08 million, up from $207.72 million year-over-year[42] - Cash flow from financing activities resulted in a net inflow of $179.50 million, compared to $111.62 million in the previous year[42] - The ending balance of cash and cash equivalents was $1.25 billion, an increase from $1.06 billion at the end of the previous year[42] Investments and Expenses - Research and development expenses for Q3 2022 amounted to CNY 22,237,239.07, an increase from CNY 18,244,320.92 in Q3 2021, representing a growth of 21.83%[33] - The company received government subsidies amounting to ¥247,424.64 during the quarter, primarily related to its pharmaceutical business[11] - The company received a total of RMB 298,534,345.93 in exit compensation from the Jiangsu Xiangshui Ecological Chemical Park Management Committee, out of a total compensation of RMB 384,555,277.93[21] Changes in Accounts - The company reported a 30.77% increase in prepaid accounts, attributed to increased procurement payments[14] - The company experienced a 723.27% increase in other receivables due to compensation payments from a subsidiary[14] - Accounts receivable increased to RMB 919,066,487.34 from RMB 759,968,112.40, representing a growth of approximately 20.93%[25] - Other receivables rose sharply to RMB 101,998,332.46 from RMB 12,389,438.11, marking an increase of around 726.5%[25] - The company reported a decrease in accounts payable from CNY 131,756,572.16 to CNY 105,173,460.43, a reduction of 20.29%[30] Equity and Ownership - The company’s total equity attributable to shareholders was ¥1,828,448,481.45, a decrease of 1.43% from the previous year[9] - The company’s weighted average return on equity was -1.51%, a decrease of 0.45 percentage points from the previous year[9] - There are no known related party transactions among the top shareholders, ensuring transparency in ownership structure[20] General Remarks - The company has not disclosed any significant new product developments or market expansions during the reporting period[21] - The company plans to continue focusing on R&D to drive future growth despite current losses[33]